Reference drugs for triple combination test drug in Russia [Design Issues]

posted by PharmCat  – Russia, 2019-11-13 22:25 (2062 d 07:55 ago) – Posting: # 20801
Views: 9,222

❝ i.e. 2 tablets. All of these drugs are reference drugs according to the GRLS system.


❝ What is your opinion which option to choose?


Hello!

Strictly for bioequivalence you should chose drug from register that have label "Reference drug". If no such drug - you should make
efficacy trial.

I heard there was a case when drug was registered in EU and BE in Russia was performed with separate reference drugs - but now this case is not approvable, but some companies try to do this.

If say strict - both cases is wrong.

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,680 registered users;
45 visitors (0 registered, 45 guests [including 11 identified bots]).
Forum time: 07:21 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5